News

All of Ferrer’s information, just a click away

normal

We spearhead two European studies that highlight the urgency of patients and experts to improve the diagnosis and treatment of pulmonary hypertension associated with interstitial lung disease

.

Wed, 11/20/2024 - 08:49

Ferrer advances research into Progressive Supranuclear Palsy (PSP) with the inclusion of the first participant in a Phase II clinical trial

.

Thu, 08/08/2024 - 08:36

Discover our 2023 Sustainability Report

.

Wed, 07/10/2024 - 09:48

Ferrer obtains the distribution rights of a potential treatment for Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF)

.

Fri, 05/24/2024 - 09:34

People living with pulmonary hypertension call for better psychological support in the absence of awareness of this severe disease

.

Sun, 04/21/2024 - 21:13

Ferrer and Verge Genomics Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635

.

Fri, 03/22/2024 - 10:52

CDP rates us among the leading companies in the fight against climate change

.

Tue, 02/06/2024 - 14:56

We are EcoVadis Platinum!

.

Wed, 01/31/2024 - 12:43

Ferrer reports top-line results from Phase III ADORE study in ALS

.

Wed, 01/10/2024 - 10:52

Ferrer obtains the highest LEED certification rating for its Barcelona offices

.

Fri, 12/22/2023 - 10:59

For requests for interviews or information, please contact the Communications Department

alternatively, please dial +34 936 003 779

See more

Business Development